VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

L. Morasca, S. Marsoni, M. Brambilla Pisoni, E. Piazza, G. Vago, W. Casali, R. Cogo, C. Bainchi, R. Scapaticci

Research output: Contribution to journalArticle

Abstract

Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.

Original languageEnglish
Pages (from-to)209-210
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume7
Issue number2-3
DOIs
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Morasca, L., Marsoni, S., Pisoni, M. B., Piazza, E., Vago, G., Casali, W., Cogo, R., Bainchi, C., & Scapaticci, R. (1982). VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. Cancer Chemotherapy and Pharmacology, 7(2-3), 209-210. https://doi.org/10.1007/BF00254551